Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
"The Report Frontier Pharma:
Liver Cancer - Identifying and Commercializing First-in-Class
Innovation provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
About
Liver
Cancer
Market
Globally, liver cancer is the sixth most
common cancer, but its poor prognosis makes it the second leading
cause of cancer-related death (Globocan, 2012). Currently, the range
of therapies is limited; the market consisted entirely of
chemotherapies for many years, and only recently have targeted
therapies begun to emerge.
The liver cancer market is segmented in
terms of its needs. Early-stage patients have access to curative
therapies such as surgical resection, and therefore have a relatively
positive outlook. However, at at the opposite end of the spectrum
patients that are diagnosed in later stages who represent the
majority of the patient population are not eligible for surgery, and
have a very poor prognosis in spite of the approvals of targeted
therapies such as Nexavar (sorafenib) and Stivarga (regorafenib).
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1287796
In stark contrast to the relatively
limited market landscape, which contains just 86 products, the liver
cancer pipeline is large, diverse and highly innovative. The pipeline
has 423 products in active development, with diversity of both
molecule type and mechanism of action. Of these, 122 are
first-in-class, and act on 109 distinct first-in-class molecular
targets. These products span a very wide range of molecular target
types including cancer immunotherapies, receptor tyrosine kinases,
targeted cytotoxic agents and kinase inhibitors, far exceeding the
scope of products present in the chemotherapy-dominated market.
Scope
The 423 products in active
development, of which 122 are first-in-class and therefore act on
completely novel targets, far exceed the scope of the current market.
How will pipeline innovation affect the future liver cancer market?
There are 109 distinct first-in-class
molecular targets currently being studied. Which of these hold the
greatest potential to improve future disease treatment with regard to
their molecular target?
The majority of first-in-class
products in development are cancer immunotherapies. Which of these
are the most promising, and how does the ratio of first-in-class
targets to first-in-class products differ by stage of development and
molecular target class?
A significant number of
first-in-class products have been identified with some prior
involvement in deals. How do deal frequency and value compare between
target families and molecule types, and which first-in-class programs
have not yet been involved in a licensing or co-development deal?
Reasons to buy
Understand the current clinical and
commercial landscape. The report includes a comprehensive study of
disease pathogenesis, diagnosis, prognosis and the treatment options
available.
Visualize the composition of the
liver cancer market in terms of dominant molecule types and targets,
highlighting what the current unmet needs are and how they can be
addressed. This knowledge allows a competitive understanding of gaps
in the market.
Analyze the liver cancer pipeline and
stratify by stage of development, molecule type and molecular target.
There are strong signs in the pipeline that the industry is seeking
novel approaches to treating liver cancer subtypes such as
hepatocellular carcinoma and cholangiocarcinoma.
Assess the therapeutic potential of
first-in-class targets. Using a proprietary molecular target matrix,
first-in-class products have been assessed and ranked according to
clinical potential.
Identify commercial opportunities in
the liver cancer deals landscape by analyzing trends in licensing and
co-development deals, and producing a list of first-in-class
therapies with no prior involvement in licensing or co-development
deals."
View
Report @
https://www.marketresearchreports.biz/reports/1287796/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market-research-reports
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 High Unmet Need and a Limited Number
of Marketed Options 4
2.2 Large, Diverse and Highly Innovative
Pipeline 4
2.3 Active Deals Landscape Reflects the
Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic
Products 6
3.2 Diversification of Molecular Targets
6
3.3 Innovative First-in-Class Product
Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy
Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Symptoms 9
4.3 Diagnosis 10
4.3.1 Clinical Presentation 10
4.3.2 Alpha-Fetoprotein 10
4.3.3 Diagnostic Imaging and Scans 10
4.3.4 Screening 10
4.3.5 Biopsy 11
4.3.6 Staging, Classification and
Prognosis 11
4.4 Epidemiology and Etiology 11
4.5 Pathophysiology 13
4.6 Risk Factors and Co-Morbidities 17
4.7 Treatment Options 17
4.8 Treatment Algorithm 18
4.9 Overview of Marketed Products for
Liver Cancer 19
4.9.1 Innovative Products in the Liver
Cancer Market 20
4.9.2 Unmet Needs 21
5 Assessment of Pipeline Product
Innovation 22
5.1 Liver Cancer Pipeline by Molecule
Type, Phase and Therapeutic Target 22
5.2 Comparative Distribution of Programs
between the Liver Cancer Market and Pipeline by Therapeutic Target
Family 26
5.3
First-in-Class Pipeline Programs 27
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1287796
About us
MarketResearchReports.biz is the most
comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment